arrow
C

Clara De Simone

Catholic University of Sacred Heart
H指数:43
被引数:7,310

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

LC-OCT for Cutaneous Lupus Erythematosus: Characterization Across Disease Subtypes and Differentiation From Rosacea

利用LC-OCT对皮肤红斑狼疮进行表征:跨疾病亚型的特征分析及与玫瑰痤疮的鉴别

2026-09-290
OAAI
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients

对BP180 C末端表位的独特反应特征了免疫检查点抑制剂相关的天疱疮,并且基于BP180胞外域的ELISA能够使部分患者的快速诊断

2026-04-080
OA
A 14-year multicentric follow-up study of atypical pemphigus variants in Italy: the VARIANT_P study

一项为期14年的意大利多中心随访研究:非典型天疱疮变异体的VARIANT_P研究

2025-11-010
PRE
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift Programs

GRINCH指数:测量圣诞节假期赠品项目期间的病人满意度

2025-10-010
OAAI
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study

银屑病患者中 guselkumab 的长期真实世界有效性与药物生存率:一项为期5年的回顾性研究

2025-09-160
OA
Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy

银屑病患者接受抗白细胞介素-17治疗期间湿疹样皮疹和念珠菌病的预测因素:意大利拉齐奥地区多中心真实世界经验研究

2025-07-013
OA
Long-Term Real-World Safety Profile of Secukinumab Assessed Through a 9-Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study

通过为期9年的临床经验评估的Secukinumab在银屑病、银屑病关节炎和强直性脊柱炎患者中的长期真实世界安全性特征:一项多中心回顾性研究的结果

2025-05-240
OAAI
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)

度普利尤单抗治疗中重度银屑病的强应答者特征:一项短期真实世界观察-IL PSO(意大利银屑病全景研究)

2025-05-150
OAAI
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis)

银屑病患者中性别对Bimekizumab应答的影响:IL PSO(意大利银屑病景观)真实世界多中心回顾性研究的结果

2025-05-130
OA
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study

古塞库单抗在患有感染性合并症、恶性肿瘤或心脏病的银屑病患者中的长期真实世界安全性研究:EARLY研究

2025-04-160
PRE
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio Experience

评估Bimekizumab在不同敏感区域治疗中重度银屑病的疗效:一项为期52周的意大利多中心真实世界拉齐奥经验

2025-04-110
OA
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
2025-04-010
OAAI